Previous Article | Next Article 
Infect Immun. 1987 December; 55(12): 2984-2992
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters.
P H Kim,
J P Iaconis and
R D Rolfe
Department of Microbiology, Texas Tech University Health Sciences Center, Lubbock 79430.
ABSTRACT
In this investigation, the role of antibodies against Clostridium difficile toxins A and B in protecting hamsters against C. difficile-associated ileocecitis was examined. We also studied the transfer of protection against C. difficile-associated intestinal disease from immunized female hamsters to their infants. Adult female hamsters immunized parenterally with toxoid A or a mixture containing both toxoids A and B were protected against clindamycin-induced C. difficile-associated fatal ileocecitis. On the other hand, hamsters immunized with toxoid B or a broth filtrate from a nontoxigenic strain of C. difficile were not protected against C. difficile-induced ileocecitis. Antibody against the immunizing toxoid could be demonstrated in both the serum and the cecal contents of hamsters. Some infant hamsters from mothers immunized with toxoid A or AB were protected against C. difficile-associated ileocecitis, while infant hamsters from mothers immunized with toxoid B or a nontoxigenic broth filtrate were not protected against disease. Neutralizing antibodies to toxins A and B could be demonstrated in both maternal milk and serum, as well as in infant serum and intestinal contents. Foster-mothering experiments demonstrated that maternal protection of infants against C. difficile-associated ileocecitis was transferred to infant hamsters through breast milk. These results suggest that toxin A may play a more important role in the pathogenesis of C. difficile-associated ileocecitis in hamsters than toxin B. Furthermore, variations in the severity of C. difficile-associated illness in infants and adults may reflect the lack or presence of passively or actively acquired immunity against C. difficile toxins.
Infect Immun. 1987 December; 55(12): 2984-2992
This article has been cited by other articles:
-
Babcock, G. J., Broering, T. J., Hernandez, H. J., Mandell, R. B., Donahue, K., Boatright, N., Stack, A. M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D. M., Thomas, W. D. Jr.
(2006). Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters. Infect. Immun.
74: 6339-6347
[Abstract]
[Full Text]
-
Tonna, I, Welsby, P D
(2005). Pathogenesis and treatment of Clostridium difficile infection. Postgrad. Med. J.
81: 367-369
[Abstract]
[Full Text]
-
Voth, D. E., Ballard, J. D.
(2005). Clostridium difficile Toxins: Mechanism of Action and Role in Disease. Clin. Microbiol. Rev.
18: 247-263
[Abstract]
[Full Text]
-
Hurley, B. W., Nguyen, C. C.
(2002). The Spectrum of Pseudomembranous Enterocolitis and Antibiotic-Associated Diarrhea. Arch Intern Med
162: 2177-2184
[Abstract]
[Full Text]
-
Mylonakis, E., Ryan, E. T., Calderwood, S. B.
(2001). Clostridium difficile-Associated Diarrhea: A Review. Arch Intern Med
161: 525-533
[Abstract]
[Full Text]
-
Kotloff, K. L., Wasserman, S. S., Losonsky, G. A., Thomas, W. Jr., Nichols, R., Edelman, R., Bridwell, M., Monath, T. P.
(2001). Safety and Immunogenicity of Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to Healthy Adults. Infect. Immun.
69: 988-995
[Abstract]
[Full Text]
-
McVay, C. S., Rolfe, R. D.
(2000). In Vitro and In Vivo Activities of Nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother.
44: 2254-2258
[Abstract]
[Full Text]
-
Giannasca, P. J., Zhang, Z.-x., Lei, W.-d., Boden, J. A., Giel, M. A., Monath, T. P., Thomas, W. D. Jr.
(1999). Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficile Disease in Hamsters. Infect. Immun.
67: 527-538
[Abstract]
[Full Text]
-
Warny, M, Fatimi, A, Bostwick, E F, Laine, D C, Lebel, F, LaMont, J T, Pothoulakis, C, Kelly, C P
(1999). Bovine immunoglobulin concentrate-Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut
44: 212-217
[Abstract]
[Full Text]
-
Kink, J. A., Williams, J. A.
(1998). Antibodies to Recombinant Clostridium difficile Toxins A and B Are an Effective Treatment and Prevent Relapse of C. difficile-Associated Disease in a Hamster Model of Infection. Infect. Immun.
66: 2018-2025
[Abstract]
[Full Text]
-
Salcedo, J, Keates, S, Pothoulakis, C, Warny, M, Castagliuolo, I, LaMont, J T, Kelly, C P
(1997). Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut
41: 366-370
[Abstract]
[Full Text]
Copyright © 1987 by the American Society for Microbiology. All rights reserved.